Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, First-in-Human, Open Label, Dose Escalation and Cohort Expansion Study of MGC028 in Participants With Advanced Solid Tumors

NCT06723236 is registered in ClinicalTrials.gov with MacroGenics as lead sponsor.

NCT NCT06723236
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06723236 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, First-in-Human, Open Label, Dose Escalation and Cohort Expansion Study of MGC028 in Participants With Advanced Solid Tumors
Lead sponsor
MacroGenics
Phase
Phase 1
Overall status
Recruiting
Start date
February 13, 2025
Completion date
April 30, 2027
Enrollment
124 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors, cholangiocarcinoma, colorectal carcinoma, nsclc adenocarcinoma, pancreatic carcinoma